The Effect of Epidural Steroid Use in Patients With Continous Epidural Block in PHN Patients.

Phase 4

• Conditions: Neuralgia,Postherpetic
• Interventions: Drug: Dexamethasone; Drug: Ropivacaine

• Registration Number: NCT03995563
• Lead Sponsor: Korea University Guro Hospital

Brief Summary

The efficiency of epidural steroid injection in patients who has postherpetic neuralgia is well known. In this study, the purpose is whether the continous epidural steroid injection is effective or not.

Detailed Description

Continous epidural injection will be done during 10 days. D group will be injected a 0.19% ropivacaine 8mL and dexametasone 1mg every other day during 10 days.

Continous epidural injection will be done during 10 days N group will be injected a 0.19% ropivacaine 8mL only every other day during 10 days

Study Timeline

• Study Start: 2019-05-15
• Status Verified: 2019-06
• Study First Submitted: 2019-06-21
• Study First Submitted QC: 2019-06-21
• Last Update Submitted: 2019-06-21
• Study First Posted: 2019-06-24
• Last Update Posted: 2019-06-24
• Primary Completion: 2020-05-30
• Study Completion: 2020-11-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Patients who has herpes zoster
• Patients has a period (at least 1month) after onset of herpes zoster
• Patients has a definite symptom along dermatome
• ASA class I - II
• Age : 18 - 80 years

Exclusion Criteria

• Patients who has a cancer
• Patients who has a neurologic, psychologic, renal, hepatic and hematologic disease
• Patients who has a other dermatologic disease
• Patients who has major operation & procedure history
• Patients who has a other pain origin
• Patients who can not be inserted epidural catheter

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
D group	Ropivacaine	0.19% Ropivacaine 8mL + Dexametasone 1mg every other day injection during 10 days
D group	Dexamethasone	0.19% Ropivacaine 8mL + Dexametasone 1mg every other day injection during 10 days
N group	Ropivacaine	0.19% Ropivacaine 8mL only every other day injection during 10 days

Primary Outcome Measures

Name	Time	Method
VAS score	up to 10 days	The investigator set the primary outcome If there is a 50% reduction of VAS score.

Trial Locations

Locations (1)

Kangnam sacred heart hospital; 🇰🇷 Seoul, Yeongdeungpo-gu, Korea, Republic of